2021
Clinical Significance of PDCD4 in Melanoma by Subcellular Expression and in Tumor-Associated Immune Cells
Tran TT, Rane CK, Zito CR, Weiss SA, Jessel S, Lucca L, Lu BY, Oria VO, Adeniran A, Chiang VL, Omay SB, Hafler DA, Kluger HM, Jilaveanu LB. Clinical Significance of PDCD4 in Melanoma by Subcellular Expression and in Tumor-Associated Immune Cells. Cancers 2021, 13: 1049. PMID: 33801444, PMCID: PMC7958624, DOI: 10.3390/cancers13051049.Peer-Reviewed Original ResearchPDCD4 expressionImproved survivalTumor-Associated Immune CellsTumor microenvironmentNeoplastic progressionBrain metastasis outcomesExtracranial metastatic diseaseMelanoma brain metastasesNatural killer cellsBrain metastasis samplesImmune cell infiltrationImmune cell subsetsMultiple tissue microarraysExpression of PDCD4Brain metastasesMetastatic diseaseClinical outcomesKiller cellsClinicopathological variablesIntracranial metastasesCell subsetsCell infiltrationCell death 4Immune cellsPrimary melanoma
2015
Lung Cancer Brain Metastases
Goldberg SB, Contessa JN, Omay SB, Chiang V. Lung Cancer Brain Metastases. The Cancer Journal 2015, 21: 398-403. PMID: 26389765, DOI: 10.1097/ppo.0000000000000146.Peer-Reviewed Original ResearchConceptsLung cancer brain metastasesCancer brain metastasesBrain metastasesCentral nervous systemLung cancerSystemic therapyNervous systemIntracranial disease burdenOverall cancer prognosisSystemic therapy optionsExtracranial diseaseSelect patientsLocal therapySignificant morbidityTumor histologyIntracranial metastasesTherapy optionsDisease burdenSurgical techniqueAppropriate treatmentDurable benefitEffective treatmentCancer prognosisPatientsMetastasis